RU2693404C2 - Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их - Google Patents
Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их Download PDFInfo
- Publication number
- RU2693404C2 RU2693404C2 RU2016106002A RU2016106002A RU2693404C2 RU 2693404 C2 RU2693404 C2 RU 2693404C2 RU 2016106002 A RU2016106002 A RU 2016106002A RU 2016106002 A RU2016106002 A RU 2016106002A RU 2693404 C2 RU2693404 C2 RU 2693404C2
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- compound
- phenyl
- synthesis
- carbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357277A FR3008978A1 (fr) | 2013-07-23 | 2013-07-23 | "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| FR13/57277 | 2013-07-23 | ||
| PCT/FR2014/051884 WO2015011396A1 (fr) | 2013-07-23 | 2014-07-22 | Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016106002A RU2016106002A (ru) | 2017-08-30 |
| RU2016106002A3 RU2016106002A3 (enExample) | 2018-03-19 |
| RU2693404C2 true RU2693404C2 (ru) | 2019-07-02 |
Family
ID=49911607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016106002A RU2693404C2 (ru) | 2013-07-23 | 2014-07-22 | Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9765056B2 (enExample) |
| EP (2) | EP3027602B1 (enExample) |
| JP (1) | JP6458028B2 (enExample) |
| KR (1) | KR102337149B1 (enExample) |
| CN (1) | CN105408321B (enExample) |
| AR (1) | AR099914A1 (enExample) |
| AU (1) | AU2014294866B2 (enExample) |
| BR (1) | BR112016001333B1 (enExample) |
| CA (1) | CA2917965C (enExample) |
| CY (1) | CY1120475T1 (enExample) |
| DK (1) | DK3027602T3 (enExample) |
| EA (1) | EA028609B1 (enExample) |
| ES (1) | ES2687475T3 (enExample) |
| FR (1) | FR3008978A1 (enExample) |
| HK (1) | HK1218753A1 (enExample) |
| HR (1) | HRP20181333T1 (enExample) |
| HU (1) | HUE039507T2 (enExample) |
| LT (1) | LT3027602T (enExample) |
| MX (1) | MX364479B (enExample) |
| NZ (1) | NZ715847A (enExample) |
| PL (1) | PL3027602T3 (enExample) |
| PT (1) | PT3027602T (enExample) |
| RS (1) | RS57545B1 (enExample) |
| RU (1) | RU2693404C2 (enExample) |
| SG (1) | SG11201600004SA (enExample) |
| SI (1) | SI3027602T1 (enExample) |
| TW (1) | TW201504224A (enExample) |
| UA (1) | UA117020C2 (enExample) |
| UY (1) | UY35653A (enExample) |
| WO (1) | WO2015011396A1 (enExample) |
| ZA (1) | ZA201600415B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105237509A (zh) * | 2015-11-20 | 2016-01-13 | 江苏瑞邦农药厂有限公司 | 一种2,2-二氟-1,3-苯并二恶茂的合成方法 |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| JP6928096B2 (ja) | 2017-01-10 | 2021-09-01 | イーティーエイチ・チューリッヒ | 細胞保護化合物及びそれらの使用 |
| WO2018181866A1 (ja) | 2017-03-31 | 2018-10-04 | 国立大学法人東京大学 | ノロウイルス抗体 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN108409580A (zh) * | 2018-02-01 | 2018-08-17 | 浙江工业大学 | 一种苄胺类化合物的合成方法 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| KR20230160303A (ko) * | 2021-03-24 | 2023-11-23 | 르 라보레또레 쎄르비에르 | ５－｛５－클로로－２－[(3s)－３－[(모르폴린－４－일)메틸]－３,４－디하이드로이소퀴놀린－２(１ｈ)－카르보닐]페닐｝－１,２－디메틸－１ｈ－피롤－３－카르복실산 유도체의 신규한 합성 방법 및 약학적 화합물의 생산을 위한 이의 용도 |
| IL317101A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of anticancer compounds and methods of using them |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
| UY40985A (es) | 2023-11-22 | 2025-06-30 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006138195A (ru) * | 2004-03-29 | 2008-05-10 | Бристол-Маерс Сквибб Компани (Us) | Антагонисты cgrp |
| WO2012162365A1 (en) * | 2011-05-25 | 2012-11-29 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| WO2013096055A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| WO2013096059A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1675832B1 (en) | 2003-10-24 | 2008-02-20 | Glaxo Group Limited | Heterocyclyl compounds |
| BRPI0514504A (pt) * | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| GB0522908D0 (en) | 2005-11-10 | 2005-12-21 | Merck Sharp & Dohme | Therapeutic agents |
| CA2859873A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| AU2012355613A1 (en) * | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| AU2012355624A1 (en) * | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357277A patent/FR3008978A1/fr not_active Withdrawn
-
2014
- 2014-07-08 UY UY35653A patent/UY35653A/es unknown
- 2014-07-21 AR ARP140102679A patent/AR099914A1/es unknown
- 2014-07-22 PL PL14758604T patent/PL3027602T3/pl unknown
- 2014-07-22 RU RU2016106002A patent/RU2693404C2/ru active
- 2014-07-22 HU HUE14758604A patent/HUE039507T2/hu unknown
- 2014-07-22 JP JP2016528587A patent/JP6458028B2/ja not_active Expired - Fee Related
- 2014-07-22 SI SI201430784T patent/SI3027602T1/en unknown
- 2014-07-22 WO PCT/FR2014/051884 patent/WO2015011396A1/fr not_active Ceased
- 2014-07-22 CN CN201480041559.7A patent/CN105408321B/zh not_active Expired - Fee Related
- 2014-07-22 LT LTEP14758604.4T patent/LT3027602T/lt unknown
- 2014-07-22 NZ NZ715847A patent/NZ715847A/en not_active IP Right Cessation
- 2014-07-22 ES ES14758604.4T patent/ES2687475T3/es active Active
- 2014-07-22 SG SG11201600004SA patent/SG11201600004SA/en unknown
- 2014-07-22 EA EA201600121A patent/EA028609B1/ru unknown
- 2014-07-22 US US14/905,877 patent/US9765056B2/en not_active Expired - Fee Related
- 2014-07-22 PT PT147586044T patent/PT3027602T/pt unknown
- 2014-07-22 BR BR112016001333-6A patent/BR112016001333B1/pt not_active IP Right Cessation
- 2014-07-22 DK DK14758604.4T patent/DK3027602T3/en active
- 2014-07-22 MX MX2016000900A patent/MX364479B/es active IP Right Grant
- 2014-07-22 TW TW103125162A patent/TW201504224A/zh unknown
- 2014-07-22 UA UAA201601398A patent/UA117020C2/uk unknown
- 2014-07-22 HK HK16106759.0A patent/HK1218753A1/zh unknown
- 2014-07-22 RS RS20180839A patent/RS57545B1/sr unknown
- 2014-07-22 AU AU2014294866A patent/AU2014294866B2/en not_active Ceased
- 2014-07-22 HR HRP20181333TT patent/HRP20181333T1/hr unknown
- 2014-07-22 KR KR1020167004577A patent/KR102337149B1/ko not_active Expired - Fee Related
- 2014-07-22 CA CA2917965A patent/CA2917965C/fr active Active
- 2014-07-22 EP EP14758604.4A patent/EP3027602B1/fr active Active
- 2014-07-22 EP EP16201228.0A patent/EP3168217A1/fr not_active Withdrawn
-
2016
- 2016-01-12 ZA ZA2016/00415A patent/ZA201600415B/en unknown
-
2017
- 2017-08-14 US US15/676,154 patent/US10662173B2/en active Active
-
2018
- 2018-07-19 CY CY20181100757T patent/CY1120475T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006138195A (ru) * | 2004-03-29 | 2008-05-10 | Бристол-Маерс Сквибб Компани (Us) | Антагонисты cgrp |
| WO2012162365A1 (en) * | 2011-05-25 | 2012-11-29 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| WO2013096055A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| WO2013096059A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
Non-Patent Citations (1)
| Title |
|---|
| Porter J et al, Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors, Bioorganic & Medicinal Chemistry Letters, 19, 1, стр.: 230-233, 2009. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10662173B2 (en) | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | |
| US11058689B2 (en) | Pyrrole compounds, a process for their preparation and pharmaceutical | |
| RU2617682C2 (ru) | Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| RU2689305C2 (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner |